+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Preparation, 99mTc-labeling, and in vitro characterization of HYNIC and N3S modified RC-160 and [Tyr3]octreotide

Preparation, 99mTc-labeling, and in vitro characterization of HYNIC and N3S modified RC-160 and [Tyr3]octreotide

Bioconjugate Chemistry 10(3): 431-438

The synthesis of conjugates of two somatostatin analogues, RC-160 and [Tyr3]octreotide with different bifunctional chelators for labeling with Tc-99m, is described. Conjugates with hydrazinonicotinamide (HYNIC) and two N3S compounds (benzoyl MAG3 and a N3S adipate derivative) were prepared on a small scale with high purity allowing evaluation of different bifunctional chelators on the same peptide without extensive peptide synthesis. High in vitro stability and retained binding affinity was found for all conjugates except for the N3S adipate. Peptide conjugates could be labeled at high specific activities (>1 Ci/micromol) with 99mTc, and different coligands were explored for the HYNIC conjugates. The resulting radiolabeled complexes were highly stable and showed binding affinity to somatostatin receptors in the nanomolar range. Varying labeling yield, stability, lipophilicity, and isomerism were found for different coligands used for labeling HYNIC conjugates, with lower lipophilicity, higher stability, and fewer coordination isomers for EDDA and tricine/nicotinic acid as ternary coligand compared to tricine. In particular, HYNIC complexes showed promising results for further in vivo evaluation.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 060123110

Download citation: RISBibTeXText

PMID: 10346875

DOI: 10.1021/bc980121c

Related references

Preparation via coligand exchange and characterization of (99mTc-EDDA-HYNIC-D-Phe1,Tyr3)Octreotide (99mTc-EDDA/HYNIC-TOC). Journal of Labelled Compounds and Radiopharmaceuticals 46(4): 307-318, 2003

A freeze-dried kit formulation for the preparation of Lys(27)(99mTc-EDDA/HYNIC)-Exendin(9-39)/99mTc-EDDA/HYNIC-Tyr3-Octreotide to detect benign and malignant insulinomas. Nuclear Medicine and Biology 42(12): 911-916, 2015

99mTc-N4-[Tyr3]Octreotate Versus 99mTc-EDDA/HYNIC-[Tyr3]Octreotide: an intrapatient comparison of two novel Technetium-99m labeled tracers for somatostatin receptor scintigraphy. Cancer BioTherapy and Radiopharmaceuticals 19(1): 73-79, 2004

Analysis of accumulation of 99mTc-octreotide and 99mTc-EDDA/HYNIC-Tyr3-octreotide in the rat kidneys. Nuclear Medicine and Biology 31(2): 231-239, 2004

Radiopharmaceutical development of a freeze-dried kit formulation for the preparation of [99mTc-EDDA-HYNIC-D-Phe1, Tyr3]-octreotide, a somatostatin analog for tumor diagnosis. Journal of Pharmaceutical Sciences 93(10): 2497-2506, 2004

Specificity and sensitivity of ⁹⁹mTc-EDDA/HYNIC-Tyr³-octreotide (⁹⁹mTc-TOC) for imaging neuroendocrine tumors. Nuclear Medicine Communications 33(1): 69-79, 2012

99mTc-HYNIC-[Tyr3]-octreotide for imaging somatostatin-receptor-positive tumors: preclinical evaluation and comparison with 111In-octreotide. Journal of Nuclear Medicine 41(6): 1114-1119, 2000

Osteomalacia-inducing renal clear cell carcinoma uncovered by 99mTc-Hydrazinonicotinyl-Tyr3-octreotide (99mTc-HYNIC-TOC) scintigraphy. Clinical Nuclear Medicine 38(11): 922-924, 2013

99mTc-HYNIC-TOC (99mTc-hydrazinonicotinyl-Tyr3-octreotide) scintigraphy identifying two separate causative tumors in a patient with tumor-induced osteomalacia (TIO). Clinical Nuclear Medicine 38(8): 664-667, 2013

Preparation, (99m)Tc-labeling, and in vitro characterization of hynic and N(3)S modified RC-160 and. Bioconjugate Chemistry 10(4): 701-702, 1999

Patient-specific radiation dosimetry of 99mTc-HYNIC-Tyr3-octreotide in neuroendocrine tumors. Journal of Nuclear Medicine 52(9): 1474-1481, 2011

Detection of somatostatin receptor-positive tumours using the new 99mTc-tricine-HYNIC-D-Phe1-Tyr3-octreotide: first results in patients and comparison with 111In-DTPA-D-Phe1-octreotide. European Journal of Nuclear Medicine 27(6): 628-637, 2000

Comparison of different methods for radiochemical purity testing of [99mTc-EDDA-HYNIC-D-Phe1,Tyr3]-octreotide. Applied Radiation and Isotopes 64(2): 194-200, 2006

Biokinetics and dosimetry in patients of 99mTc-EDDA/HYNIC-Tyr3-octreotide prepared from lyophilized kits. Applied Radiation and Isotopes 64(7): 792-797, 2006

99mTc-EDDA-HYNIC-Tyr3-octreotide for detection of somatostatin receptor positive tumors and first experience in patients. Journal of Nuclear Medicine 41(5 Suppl ): 149P-150P, 2000